A high frequency of MSH6 G268A polymorphism and survival association in Glioblastoma

International Journal of Neuroscience

Volumn 123, Issue 2, 2012, Pages 114-120

  Pei, Chunying ^a,b   Chen, Hui ^a   Jia, Xiuzhi ^a,b   Yan, Lei ^a,b   Zou, Yan ^a,b   Jiang, Chuanlu ^a   Jin, Hua ^a   Kang, Chunsheng ^c   Jiang, Tao ^d   Ren, Huan ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Immunity and Infection Key Laboratory of Heilongjiang Province   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme (GBM); MSH6; Single nucleotide polymorphism (SNP)

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN; MUTS HOMOLOG 6; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; EXON; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDLINE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PROMOTER REGION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

EID: 84872706263     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.738735     Document Type: Article

References (32)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109. (Pubitemid 47103521)
2. Mathieu D, Fortin D. The role of chemotherapy in the treatment of malignant astrocytomas. Can J Neurol Sci. 2006;33:127-40. (Pubitemid 43845165)
3. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: A review of its discovery, chemical properties, pre-Clinical development and clinical trials. Cancer Treat Rev. 1997;23:35-61. (Pubitemid 27273454)
4. Shi L, Zhang S, Feng K,Wu F,Wan Y,Wang Z, Zhang J,Wang Y, Yan W, Fu Z, You Y. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012; 40:119-29.
5. Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, Ballman KV, Giannini C, Sarkaria JN. Expression of CD74 in high grade gliomas: A potential role in temozolomide resistance. J Neurooncol. 2010;100:177-86.
6. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB,Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-4.
7. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-Mediated cell death. Cancer Res. 2005;65:6394-400. (Pubitemid 40994427)
8. Liu L, Gerson SL. Targeted modulation ofMGMT: Clinical implications. Clin Cancer Res. 2006; 12:328-31. (Pubitemid 43166117)
9. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD, Modrich P.Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 1997;57:2933-6. (Pubitemid 27315042)
10. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de TN, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003. (Pubitemid 40349502)
11. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, RigginsG, Roy JE, Levine KK, MuellerW, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66:3987-91.
12. Yip S, Miao J, CahillDP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res. 2009;15:4622-9.
13. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13:2038-45. (Pubitemid 46649870)
14. Nicolaides NC, Palombo F, Kinzler KW, Vogelstein B, Jiricny J. Molecular cloning of the N-Terminus of GTBP. Genomics. 1996;31:395-97. (Pubitemid 26059043)
15. Parc YR, Halling KC, Wang L, Christensen ER, Cunningham JM, French AJ, Burgart LJ, Price-Troska TL, Roche PC, Thibodeau SN. HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res. 2000;60:2225-31. (Pubitemid 30225187)
16. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, Kolodner RD, Fox E. Structure of the human Mut-Salpha DNA lesion recognition complex. Mol Cell. 2007;26: 579-92.
17. Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van Der Zee AG, Hollema H, Kleibeuker JH, Buys CH, Hofstra RM. Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet. 1999;65:1291-8. (Pubitemid 30460379)
18. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res. 2008;14: 4859-68.
19. SchaichM, Kestel L, PfirrmannM, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol. 2009;20:175-81.
20. Hegde M, Blazo M, Chong B, Prior T, Richards C. Assay validation for identification of hereditary nonpolyposis colon cancer-Causing mutations in mismatch repair genes MLH1, MSH2, and MSH6. J Mol Diagn. 2005;7:525-34. (Pubitemid 41479719)
21. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest. 2007;87:392-97. (Pubitemid 46474563)
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96. (Pubitemid 40349501)
23. Conde J, Silva SN, Azevedo AP, Teixeira V, Pina JE, Rueff J, Gaspar JF. Association of common variants in mismatch repair genes and breast cancer susceptibility: A multigene study. BMC Cancer. 2009;9:344.
24. Smith TR, Levine EA, Freimanis RI, Akman SA, Allen GO, Hoang KN, Liu-Mares W, Hu JJ. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis. 2008;29:2132-8.
25. Curtin K, Samowitz WS, Wolff RK, Caan BJ, Ulrich CM, Potter JD, Slattery ML. MSH6 G39E polymorphism and CpG island methylator phenotype in colon cancer. Mol Carcinog. 2009;48:989-94.
26. Campbell PT, Curtin K, Ulrich CM, Samowitz WS, Bigler J, Velicer CM, Caan B, Potter JD, Slattery ML. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut. 2009;5:661-67.
27. Song H, Ramus SJ, Quaye L, DiCioccio RA, Tyrer J, Lomas E, Shadforth D, Hogdall E, Hogdall C, McGuire V, Whittemore AS, Easton DF, Ponder BA, Kjaer SK, Pharoah PD, Gayther SA. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis. 2006;27:2235-42. (Pubitemid 44644812)
28. Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, Kelsey KT, Marsit CJ, Moore JH, Karagas MR. Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet. 2009;125:527-39.
29. Picelli S, Zajac P, Zhou XL, Edler D, Lenander C, Dalen J, Hjern F, Lundqvist N, Lindforss U, Pahlman L, Smedh K, Tornqvist A, Holm J, Janson M, Andersson M, Ekelund S, Olsson L, Lundeberg J, Lindblom A. Common variants in human CRC genes as low-risk alleles. Eur J Cancer. 2010;46:1041-8.
30. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS. O6-Methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res. 1999;5:807-14. (Pubitemid 29180832)
31. Wahlberg SS, Schmeits J, Thomas G, Loda M, Garber J, Syngal S, Kolodner RD, Fox E. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res. 2002;62:3485-92. (Pubitemid 34651396)
32. Worrillow LJ, Travis LB, Smith AG, Rollinson S, Smith AJ, Wild CP, Holowaty EJ, Kohler BA, Wiklund T, Pukkala E, Roman E,MorganGJ, Allan JM. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res. 2003; 9:3012-20. (Pubitemid 36993261)